Capecitabine Monotherapy as Palliative Treatment for Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Table 1

Patients and disease characteristics ( =51).

Characteristics	Number/median (frequency/IQR)
Age at diagnosis	42 (35.5–52.5)
Sex
Male	39 (76.5)
Female	12 (23.5)
ECOG-PS before starting capecitabine
0/1	34 (66.7)
2	17 (33.3)
History of smoking
Present	8 (15.7)
Absent	28 (54.9)
NA	15 (29.4)
Stage at initial diagnosis
I	0
II	1
III	5 (9.8)
IVA	21 (43.1)
IVB	24 (47.1)
Metastatic sites
Lung	28 (54.9)
Liver	17 (33.3)
Bone	24 (47.1)
Brain	4 (7.8)
Recurrence sites	27 (52.9)
Local only	4 (7.8)
Distant	15 (29)
Both	8 (15.7)
Prior chemotherapy	51 (100)
First-line:
Platinum-based	51 (100)
With taxane	21 (41.1)
With anthracycline	27 (53)
With gemcitabine	3 (5.9)
Second-line:
Platinum-based	17 (33)
With taxane	15 (29.4)
With gemcitabine	2 (3.9)
Monotherapy	23 (45)
Taxane	19 (37.2)
Platinum	3 (5.9)
Gemcitabine	1 (1.9)
Radiation therapy
Concurrent chemoradiotherapy	47 (92)
Reirradiation	20 (39.2)
Capecitabine used as
First recurrence	11 (21.6)
Second-line	18 (35.3)
Third-line	22 (43.1)

Abbreviations: ECOG-PS: Eastern Cooperative Oncology Group Performance Status; HFS: hand-foot syndrome; IQR: interquartile range.